Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath.
When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along with exercise, their exercise capacity increased by 45.8% compared to those receiving a placebo. The Physacto trial is a part of the Tovito Phase III clinical trial, investigating the efficacy of Respimat as a maintenance therapy for COPD.
&#...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Respiratory Boehringer Ingelheim Pharmaceuticals Source Type: news
Tiotropium RESPIMAT ® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 5, 2016 Category: Research Source Type: news
New Data: STIOLTO(R) RESPIMAT(R) (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
RIDGEFIELD, Conn., Sept. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COP... Biopharmaceuticals, Devices, Drug Delivery Boehringer Ingelheim, STIOLTO RESPIMAT, tiotropium, olodaterol, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 5, 2016 Category: Pharmaceuticals Source Type: news
New Data: STIOLTO ® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news
Phase III results: tiotropium* Respimat < sup > ® < /sup > effective in symptomatic asthma patients despite at least ICS †/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Phase III results: tiotropium* Respimat < sup > ® < /sup > is effective in symptomatic asthma patients irrespective of their allergic status
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA < sup > ® < /sup > in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA < sup > ® < /sup > in both available formulations as the world ' s leading maintenance therapy for chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat < sup > ® < /sup > effective across asthma severities "
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat < sup > ® < /sup > significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New Analyses: Adding SPIRIVA < sup > ® < /sup > Respimat < sup > ® < /sup > Effective for Uncontrolled Asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
SPIRIVA < sup > ® < /sup > RESPIMAT < sup > ® < /sup > Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat < sup > ® < /sup > to the treatment of asthma in adults aged 18 years and over
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Additional results from post-hoc analysis underline effectiveness of SPIRIVA < sup > ® < /sup >
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva < sup > ® < /sup > ) alone
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New large-scale study to investigate effect of tiotropium + olodaterol Respimat < sup > ® < /sup > on exacerbations in COPD
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
